©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Serine Protease Inhibition by Insect Peptides Containing a Cysteine Knot and a Triple-stranded -Sheet (*)

(Received for publication, March 29, 1995; and in revised form, June 12, 1995)

Christine Kellenberger (1)(§) Christian Boudier (2) Isabel Bermudez (3) Joseph G. Bieth (2) Bang Luu (1) Hélène Hietter (1)

From the  (1)Laboratoire de Chimie Organique des Substances Naturelles, Université Louis Pasteur, URA 31 CNRS, 67084 Strasbourg Cedex, France, the (2)Laboratoire d'Enzymologie, INSERM U 392, Université Louis Pasteur, 67400 Illkirch, France, and the (3)School of Biological and Molecular Sciences, Oxford Brookes University, Headington, Oxford OX3 0BP, United Kingdom

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Three insect peptides showing high sequence similarity and belonging to the same structural family incorporating a cysteine knot and a short three-stranded antiparallel beta-sheet were studied. Their inhibitory effect on two serine proteases (bovine alpha-chymotrypsin and human leukocyte elastase) is reported. One of them, PMP-C, is a strong alpha-chymotrypsin inhibitor (K = 0.2 nM) and interacts with leukocyte elastase with a K of 0.12 µM. The other two peptides, PMP-D2 and HI, interact only weakly with alpha-chymotrypsin and do not inhibit leukocyte elastase. Synthetic variants of these peptides were prepared by solid-phase synthesis, and their action toward serine proteases was evaluated. This enabled us to locate the P1 residues within the reactive sites (Leu-30 for PMP-C and Arg-29 for PMP-D2 and HI), and, interestingly, variants of PMP-D2 and HI were converted into powerful inhibitors of both alpha-chymotrypsin and leukocyte elastase, the most potent elastase inhibitor obtained in this study having a K of 3 nM.


INTRODUCTION

In the last decade, naturally occurring serine protease inhibitors (1) have been the focus of many studies, mainly for two reasons: first, the target proteins control functions in a variety of fundamental proteolytic processes in humans and mammals (blood clotting, digestion, inflammation, fibrinolysis), in invertebrates such as insects (immune system, digestion, protection against their predators) or worms (protection against their host), and plants (protection against insect attack); second, low molecular weight inhibitors of serine proteases have been attractive tools for studying the general aspects of protein conformation and protein-protein interactions(2) . In the present study, we report the inhibitory properties of three homologous peptides (primary and tertiary structures) toward alpha-chymotrypsin, trypsin, and human leukocyte elastase.

We have previously isolated two peptides, PMP-C and PMP-D2, from the brain and the fat body of the insect Locusta migratoria(3) . These peptides are composed of 36 and 35 residues, respectively, and are cross-linked by three disulfide bonds. The Thr-9 of PMP-C has an uncommon O-glycosidic linkage to a single fucose moiety. There is 40% strict identity between PMP-C and PMP-D2 with conservation of the Cys positions(3) . Moreover, they are located on the same peptidic precursor, and, by Northern blot analysis, it has been shown that the gene encoding this precursor is mainly transcribed in the fat body(4) . In this paper, we describe the isolation and characterization of HI, a novel locust peptide.

Because the isolation from insect extracts is time-consuming and yields only small amounts of peptides, we have prepared, at a reasonable scale (5-10 mg), by solid-phase synthesis, PMP-D2 (5) and PMP-C with and without the fucose moiety. (^1)Although they are small peptides with a high disulfide content, no sequence similarities could be found when comparing them with small toxins or small protease inhibitors. However, the milligram quantities of PMP-D2 obtained by solid-phase synthesis enabled us to study its tertiary structure by two-dimensional nuclear magnetic resonance, which showed interesting similarities with the tertiary fold of both -conotoxin GVIA, a calcium channel blocker, and the Ascaris chymotrypsin/elastase inhibitor(6) . This prompted us to evaluate their protease inhibitory activity.

In the present paper, we report on the inhibitory activity of PMP-C, PMP-D2, and HI toward serine proteases (bovine alpha-chymotrypsin, human leukocyte elastase, and porcine trypsin) using the natural and synthetic peptides. Since the P1 residue (7) within the reactive site of serine protease inhibitors determines the specificity for the cognate enzyme, mutational or synthetic changes of the P1 residue and/or replacement of active site residues should greatly influence both the specificity and the potency of the inhibition. For that reason, we have prepared by solid-phase synthesis variants (^2)of PMP-C, PMP-D2, and HI, in which one or two residues within the reactive site have been changed, and we have evaluated their inhibitory properties toward HLE, (^3)alpha-chymotrypsin and trypsin.


EXPERIMENTAL PROCEDURES

Materials

Chemicals

The acetonitrile, trifluoroacetic acid of HPLC quality, methyl tert-butyl ether, and dimethylformamide (DMF) were from SDS (Seltz, France). The N-ethyldiisopropylamine (DIEA) was obtained from Merck (Darmstadt, Germany). The Wang (p-benzyloxybenzyl alcohol) resins came from Novabiochem (Meudon, France), and N-Fmoc amino acids derivatives were purchased from Millipore (St. Quentin Yvelines, France) and Neosystem Laboratoire (Strasbourg, France). The BOP reagent (benzotriazolyl-N-oxy-tris-(dimethylamino)phosphonium hexafluorophosphate) and trifluoroacetic acid were from Neosystem Laboratoire.

Enzymes

Human leukocyte elastase (HLE) was isolated from purulent sputum (8) and active site-titrated using acetyl-Ala(2)-AzaAla-p-nitrophenyl ester (9) from Enzyme System Products (Livermore, CA). Porcine trypsin and bovine chymotrypsin were purchased from Biosys (Compiègne, France) and active site-titrated using p-nitrophenyl p-guanidinobenzoate (10) and N-trans-cinnamoylimidazole (11) from Sigma, respectively.

Substrates

Suc-Ala(3)-pNA, MeO-Suc-Ala(2)-Pro-Val-pNA, glutaryl-Phe-pNA, Suc-Ala(2)-Pro-Phe-pNA, and benzoyl-Arg-pNA were from Bachem (Bubendorf, Switzerland). Suc-Ala(3)-pNA stock solutions were prepared in N-methylpyrrolidone. All other substrate stock solutions were prepared in DMF.

Methods

Isolation of the Natural Peptides (PMP-D2, PMP-C, and HI) from the Hemolymph of the Insect L. migratoria and Primary Structure Determination of HI

The hemolymph of fifth instar larvae(1800) of the African locust L. migratoria (kindly supplied by the Laboratoire de Biologie Générale de l'Université Louis Pasteur, Strasbourg, France) was collected directly into Eppendorf tubes and was centrifuged at 900 times g for approximately 30 s at 4 °C to separate the hemocytes from the plasma and was kept on ice. Plasma samples were pooled (70 ml) and applied (3 ml per cartridge) onto C18 Sep-Pak cartridges (Waters). The elution was performed with increasing concentrations of acetonitrile in water (18, 36, and 60%). The 36% acetonitrile fractions were purified by C18 RP-HPLC using an analytical column (0.46 times 25 cm) packed with 5-µm-wide pore (30 nm) Vydac particles. A linear gradient from 0 to 60% acetonitrile in 0.1% trifluoroacetic acid over 60 min, at a flow rate of 1 ml/min was used. The peaks were collected manually and, if necessary, repurified on the same column with a shallower gradient (a stepwise gradient from 5 to 11% (or 15%) acetonitrile over 10 min and from 11% (or 15%) to 35% (or 39%) acetonitrile over 40 min). They were estimated to be 95% pure on analytical RP-HPLC, and the amount of natural PMP-D2, PMP-C, and HI obtained from 70 ml of hemolymph was 1 mg, 1 mg, and 60 µg, respectively.

The authenticity of the PMP-C and PMP-D2 was assessed by electrospray mass spectrometry on a VG BioTech BIO-Q mass spectrometer and by coelution with PMP-C and PMP-D2 obtained after isolation from the brain and the fat body of the same insect(3) .

The peptide referred to as HI was reduced and alkylated by 4-vinylpyridine (as described in (3) ) and was then subjected to automated Edman degradation on an Applied Biosystems Sequencer, model 471A in the liquid pulse mode, which yielded a 35-amino acid sequence (Fig. 1). The molecular mass of HI, as determined by electrospray mass spectrometry, was 3716.43 ± 0.18 Da, which is in excellent agreement with the sequencing data (deduced mass M = 3722.28 Da minus 6 for 3 disulfide bridges).


Figure 1: A, amino acid sequence of the peptide named HI and comparison with the sequence of PMP-D2 (72% identity); B, sequence comparison between PMP-C and PMP-D2 (a gap is introduced to maximize the homology between the two sequences).



Solid-phase Peptide Synthesis

The synthesis of PMP-D2 (5) and PMP-C^1 was performed as described elsewhere. HI and all the synthetic variants of PMP-C and PMP-D2 were synthesized manually, via Fmoc chemistry, starting with approximately 0.25 mmol of Wang (p-benzyloxybenzyl alcohol) resins. Amino acids were coupled as N-Fmoc derivatives with the following side chain protections: trityl for Asn, Cys, and Gln; t-butyl for Asp, Glu, Ser, and Thr; t-butoxycarbonyl for Lys, and Trp; 2,2,5,7,8-pentamethyl chroman-6-sulfonyl for Arg; and Met was coupled unprotected. The coupling reactions were achieved in DMF using 3 eq of BOP to activate the carboxyl function, 3 eq of protected amino acid, and 9 eq of DIEA. The completion of the couplings was assessed by a qualitative ninhydrin test. If necessary, double couplings were achieved with 5 eq of amino acids. The removal of the Fmoc protecting group was achieved with 25% piperidine in DMF. The side chain deprotection and the cleavage of the peptide from the resin (100 mg) was done with the standard trifluoroacetic acid procedure: trifluoroacetic acid/ethanedithiol/thioanisol/H(2)O/phenol (10 ml/0.25 ml/0.5 ml/0.5 ml/0.75 g) at room temperature for 2 h. The trifluoroacetic acid solution was vacuum-filtered into cold methyl tert-butyl ether (30 ml). The methyl tert-butyl ether suspension was centrifuged for 5 min at 2000 times g at room temperature. The supernatant was discarded, and the precipitate was resuspended in methyl tert-butyl ether (30 ml). This procedure was repeated twice, and the precipitate was finally dissolved in 10% acetic acid and lyophilized.

Disulfide Bond Formation and Purification of the Synthetic Peptides

The crude peptides (1 mg/ml) were air-oxidized in water (pH 8-9 adjusted with DIEA) without preliminary purification. The completion of oxidation (usually 18 h) was checked by HPLC, and the reaction was acidified with trifluoroacetic acid before application on a semi-preparative C18 RP-HPLC column (2.2 times 25 cm) packed with 10-µm-wide pore (300 nm) Vydac particles. Elution was performed at a flow rate of 10 ml/min with a linear gradient of 0-60% acetonitrile in 0.1% trifluoroacetic acid over 60 min. The collected fractions were pooled, concentrated by lyophilization, and repurified using a shallower gradient (a stepwise gradient from 5-11% (or 15%) acetonitrile over 10 min and from 11% (or 15%) to 35% (or 39%) acetonitrile over 40 min).

Peptide purity was estimated to be 95% by analytical RP-HPLC using a stepwise gradient as for the purification of HI. Overall yields, based on resin, were usually between 2 and 3%. The authenticity of the synthetic peptides was checked by electrospray mass spectrometry. Table 1shows the deduced mass from Edman degradation and the measured mass of the different variants (the 6-Da difference between the mass deduced from amino acid sequence and that measured by electrospray mass spectrometry is due to the involvement of the 6 Cys in 3 disulfide bonds).



Determination of the Net Peptide Content in Peptide Inhibitors

Peptide concentrations were deduced from the molecular mass and the extinction coefficient, a parameter measured as described by Van Iersel et al.(12) .

Serine Protease Inhibition

Protease concentrations mentioned in this article refer to the concentration of active enzymes. The Michaelis constants K were determined using standard procedures. Unless otherwise stated, all kinetic experiments were performed at 25 °C in 50 mM Tris containing 20 mM CaCl(2), pH 8.0, a solution that will be referred to as ``the buffer'' throughout the text.

Measurement of Equilibrium Dissociation Constant K(i)

K(i) was calculated from equilibrium titration experiments. 990-µl reaction mixtures containing constant amounts of enzyme and increasing amounts of inhibitor in the buffer were incubated at 25 °C for 15 min, an incubation time that was sufficient to ensure maximum enzyme inhibition under our experimental conditions. Reactions were started by the addition of 10 µl of substrate stock solution, and the release of p-nitroanilide was followed at 410 nm using a Uvicon 941 spectrophotometer (Kontron) and recorded until the rate of substrate breakdown remained constant.

Trypsin inhibition was assessed by reacting 4 µM enzyme with 16 µM peptide for 30 min at 25 °C and measuring the enzyme activity with 1 mM benzoyl-Arg-pNA.

Measurement of Association (k) and Dissociation (k) Rate Constants

Kinetics of HLE and chymotrypsin inhibition by the native and synthetic peptides were measured using the progress curves method(13) . Enzyme was dropped into a spectrophotometer cuvette containing substrate and inhibitor in the buffer. Pseudo-first order conditions, [I](0) geq 10 times [E](0) ([I](0) is the initial inhibitor concentration and [E](0) the initial enzyme concentration), were used. The release of p-nitroanilide was followed at 410 nm using a Cary 2200 spectrophotometer (Varian) on line with an IBM PS2 Model 30 microcomputer. Nonlinear regression analysis of progress curves was done using the Enzfitter software (Biosoft, Cambridge, UK).


RESULTS

Isolation and Primary Structure Determination of a Novel Peptide, HI, from the Hemolymph of L. migratoria

While purifying from the hemolymph PMP-C and PMP-D2 as reference compounds, a novel peptide, named HI, was isolated. The sequencing of HI, carried out by automated Edman degradation, showed a 72% strict identity with PMP-D2 (Fig. 1). The molecular mass, measured by electrospray mass spectrometry, was 3716.43 Da. This value differs by 6 Da from the data obtained by Edman degradation (3722.28 Da), thus suggesting that the 6 Cys are all involved in 3 disulfide bonds. Moreover, because of its high homology with PMP-D2, it is likely that the disulfide pairing is the same as in PMP-D2(6) .

Protease Inhibition by Natural and Synthetic PMP-C, PMP-D2, and HI

Preliminary experiments have shown that only PMP-C inhibits HLE. By contrast, chymotrypsin was found to interact with the 3 peptides. Interestingly, none of the peptides was found to inhibit porcine trypsin in our experimental conditions.

Fig. 2shows the effect of increasing quantities of synthetic PMP-D2 on constant quantities of chymotrypsin. Substrate was added to equilibrium mixtures of enzyme and inhibitor. The release of p-nitroanilide versus time was stable after 20-30 s indicating that E, I, S (enzyme, inhibitor and substrate, respectively), and their complexes have reached their equilibrium. Calculation of the best estimate of the substrate-dependent equilibrium constant K(i) was performed by nonlinear regression analysis of the experimental data based on (13) :


Figure 2: Inhibition of alpha-chymotrypsin by PMP-D2. A constant alpha-chymotrypsin concentration (6 µM) was incubated at 25 °C for 10 min with increasing concentrations of PMP-D2 (5.2 to 52 µM). After addition of glutaryl-Phe-pNA (1.4 mM, final concentration), the release of p-nitroanilide was followed at 410 nm. Fractional activity (a) is defined in the text. Experimental points (+) and theoretical line(-) generated using and the best estimate of K.



where a, the enzymic fractional activity, is the ratio of the velocity in the presence of inhibitor to that in its absence. The true K(i) (Table 2) was deduced from K(i) using the following relationship: K(i) = K(i)/(1 + [S](0)/K(m)), where[S](0) is the initial substrate concentration. The K(i) value for natural PMP-D2 was shown to be identical with that of the synthetic peptide (Table 2).



Equilibrium dissociation constants governing the interactions between chymotrypsin and synthetic HI and between HLE and PMP-C (natural and synthetic nonfucosylated) were determined using similar equilibrium titration experiments (Table 2).

Since PMP-C (natural and synthetic nonfucosylated) binds chymotrypsin very tightly, K(i) was obtained through k and k. These parameters were determined using the progress curves method(13, 14) . A typical curve illustrating chymotrypsin inhibition by nonfucosylated PMP-C is shown in the inset of Fig. 3A. The curve is biphasic, i.e. the pre-steady state release of product is followed by a steady state, confirming that PMP-C reversibly interacts with chymotrypsin. Since no significant decrease of the initial substrate concentration occurred during the progress of the reaction and, since I(0) geq 10 times E(0), product accumulation versus time can be described by the following equation:


Figure 3: A, effect of increasing concentrations of synthetic nonfucosylated PMP-C (0.14 to 0.72 µM) on the apparent first order rate constant (k). The inset shows a progress curve for the inhibition of alpha-chymotrypsin: the substrate Suc-Ala(2)-Pro-Phe-pNA (0.25 mM) and PMP-C (0.43 µM) were allowed to equilibrate in the cuvette, and the reaction was initiated by the addition of alpha-chymotrypsin (10 nM, final concentration), the release of p-nitroanilide was followed for 6 min. The theoretical curve is generated using and the best estimate of k. B, effect of increasing concentrations of Suc-Ala(2)-Pro-Phe-pNA (1/F) on the apparent first order rate constant (k) of the alpha-chymotrypsinbulletPMP-C complex (F = 1 + [S](0)/K).



where P is the product concentration, v(z) is the rate of substrate hydrolysis at t = 0, v(s) is the steady state velocity. k, the apparent first order rate constant governing the pre-steady state was calculated from the experimental data by nonlinear regression analysis using . Chymotrypsin inhibition was studied using synthetic nonfucosylated PMP-C concentrations varying from 0.14 to 0.72 µM. Fig. 3A shows the effect of [I](0), the initial inhibitor concentration on the apparent rate constant k; the linear increase of k strongly suggests that no reaction intermediate accumulates (within the range of inhibitor concentrations used) and that E and I interact according to a simple bimolecular and reversible mechanism.

Fig. 3B shows the effect of the initial substrate concentration on k; the linear increase of k with 1/F (F = 1 + [S](0)/K(m)) indicates that inhibitor and substrate compete for the binding to the enzyme. Hence, k and I(0) are related as follows(15) :

where K(m) is the Michaelis constant. k, the second order rate constant was calculated from the slope of the linear curve shown in Fig. 3A using K(m) = 23 µM. k, the first order dissociation rate constant, is given by the intercept of the curve with the ordinate. The values of k, k, and K(i) (K(i) = k/k) of fucosylated and nonfucosylated PMP-C are shown in Table 2; these kinetic constants are similar, indicating that the fucose moiety does not affect chymotrypsin inhibition.

The inhibition properties (toward chymotrypsin and HLE) of the variants of PMP-C, PMP-D2, and HI were examined using similar methods, and the results are given in Table 2.

Determination of the P1 Amino Acid by Synthetic Replacement of the Amino Acid at the Presumed Site

It is well documented that alpha-chymotrypsin inhibitors usually have bulky and aromatic amino acid residues such as Tyr, Phe, Leu, or Met as their P1 residue, while elastases have moderately large hydrophobic residues such as Leu, Met, Ala, Val as P1, but never Phe(1) . Therefore, we hypothesized that the most likely P1 residue in PMP-C is Leu-30, which could account for its inhibitory effect toward both alpha-chymotrypsin and HLE. Leu-30 was indeed the most probable location for the P1 amino acid, since it is the only Leu residue in the sequence of PMP-C (Fig. 1) and since it is located in an exposed and accessible region of the peptide, immediately after the third strand of the beta-sheet. To test this hypothesis, we prepared a synthetic variant of PMP-C in which Leu-30 was replaced by a Val residue. The choice of Val was based on the following considerations. Val has never been reported as the P1 amino acid in chymotrypsin inhibitors; the change of Leu to Val should has little if any effect on the tertiary fold of PMP-C; small peptidic inhibitors are supposed to react in a substrate-like manner, and Val is a P1 residue found in the substrates of HLE(16) .

As shown in Table 2, the L30V variant lost most of its ability to inhibit alpha-chymotrypsin. However, it retained its weak activity toward HLE (Table 2). The spectacular change in the inhibition of alpha-chymotrypsin observed with the L30V variant indicated that it was possible to lose specifically the inhibitory activity toward chymotrypsin, while retaining the anti-elastase property. Therefore, we concluded that the changed amino acid Leu was the P1 residue, the decrease in affinity being due to an inappropriate P1 residue and not to the misfolding of the PMP-C variant.

Confirmation of the Determined P1 Residue by Conversion of PMP-D2 and HI into Powerful alpha-Chymotrypsin Inhibitors

The comparison of PMP-C with PMP-D2 and HI sequences enabled us to locate the reactive site of PMP-D2 and HI by simply superimposing them: CTLKAC, PMP-C; CTRKGC, PMP-D2; CTRKAC, HI.

Thus, the most probable reactive sites P1-P`1 in PMP-D2 and HI are Arg-29-Lys-30. To confirm this hypothesis, the presumed P1 residues (Arg) were replaced by Leu in PMP-D2 and HI in order to have the same reactive site Leu-Lys as in PMP-C. The potency of both R29L variants toward alpha-chymotrypsin inhibition was increased significantly, and they were both converted into HLE inhibitors. The PMP-D2 variant was found to be the strongest inhibitor of HLE obtained in this study (Table 2).

When comparing the amino acids within the reactive site P3-P`3 of PMP-C and the R29L variants of HI and PMP-D2, one can notice the strict identity of the recognition site between PMP-C and the HI variant (CTLKAC), whereas PMP-D2 variant has a Gly in the P`2 position (CTLKGC) instead of Ala; these results are indicative of an Ala in position P`2 which may be preferable to Gly for alpha-chymotrypsin inhibition, while the contrary is true for elastase inhibition.

Design of a Better Elastase Inhibitor

Several elastase inhibitors have been reported to have a Met residue at P`1; for instance, mucous proteinase inhibitor (17) and Ascaris chymotrypsin/elastase inhibitor (18) have Leu-Met as P1-P`1 reactive site. Therefore, considering the strongest elastase inhibitor obtained in this study (PMP-D2 variant R29L), a double variant R29L/K30M (with Met as P`1) was designed in order to improve the binding to HLE. Indeed, the variant R29L/K30 M is 4-fold stronger than the previous one with a K(i) of 3 nM, confirming the importance of the Met in position P`1.

To investigate the role of the residues beyond the P1-P`1 bond, we have prepared a double variant of PMP-C: K31M/A32G (which has the same P3-P`3, CTLMGC, as the most powerful elastase inhibitor R29L/K30M variant of PMP-D2) and examined its inhibitory activity; this variant is still 7- to 8-fold weaker HLE inhibitor than the double variant of PMP-D2 (a Met as P`1, in this case, does not increase the potency toward HLE). In contrast, the double variant of PMP-C is more effective toward alpha-chymotrypsin than the PMP-D2 double variant. Thus, the residues beyond the P1-P`1 bond seem to have an effect on the specificity toward proteases, and variants of PMP-D2 seem to be more specific toward elastases than the variants of PMP-C.


DISCUSSION

The results of this study clearly show that PMP-C and PMP-D2 differ significantly with respect to their selectivity toward serine proteases, even though they exhibit a high sequence homology (45%) and are structurally related. (^4)It seems reasonable to hypothesize that a common ancestor might have adapted for specific and diverse biological functions by punctual mutations that do not affect the overall three-dimensional structure. In that respect, it is remarkable that a unique substitution in the reactive site of PMP-D2 (from Arg to Leu) is sufficient to restore the serine protease inhibitory activity.

Since PMP-C is a tight-binding reversible inhibitor and has a small and compact shape and an exposed binding loop, we propose to include it in the large group of the ``small canonical tight-binding serine protease inhibitors.'' This group of protease inhibitors consists of 16 different families and includes peptides ranging from 29 to 120 amino acids(2) . Interestingly, the peptides of this group are structurally unrelated, but share some properties such as hydrophobic cores (often maintained by disulfide bonds), stability toward unfolding, and, more remarkably, an exposed binding loop (containing the scissile P1-P`1 bond) that fits into the active site cleft of the serine protease. The specificity of serine protease inhibitors is significantly, but not exclusively, determined by the nature of the P1 residue in the reactive site. Although in most families of proteins, the active regions are highly conserved, in the serine protease inhibitors, there is no consensus sequence for the reactive site emerging yet. Indeed, retention of activity in these proteins exists even though the P1 residue has been changed(1) . In some cases, substitutions lead to a predictable change in the inhibitory specificity(17, 19, 20, 21) .

Taking into account the variability of the P1 region, we have designed ``variants'' of PMP-C, PMP-D2, and HI by targeting precisely the amino acid replacement. The aim of this study was to determine the P1 residue of the peptides and to increase the affinity toward HLE, since a variety of elastase inhibitors have been shown to be effective in animal models of emphysema, acute respiratory distress syndrome, rheumatoid arthritis, cystic fibrosis, bronchitis, or acute pancreatitis.

We have proved that Leu-30 is actually the P1 position by modulating successfully the inhibitory properties of PMP-C (maintaining its activity toward HLE and decreasing it toward alpha-chymotrypsin) with the L30V variant. This result is unambiguously confirmed in the case of PMP-D2 and HI, where Arg-29 (equivalent to Leu-30 in PMP-C) was replaced by a Leu; the R29L variants are potent alpha-chymotrypsin inhibitors and they present a reasonable affinity toward HLE.

Surprisingly, the replacement of the P1 = Leu-30 (in PMP-C) by Val increased the affinity toward HLE by a factor of 3 only. Indeed, several novel elastase inhibitors were obtained by replacing the P1 for Val(19, 20, 21) . Our results highlight the significant role of the nature of the amino acids within the reactive site other than the P1 side chain for elastase inhibition. We therefore evaluated the effect of the P`1 residue (large and basic side chain) by replacing the Lys-30 in the R29L variant of PMP-D2 (which was presently the most effective HLE inhibitor) by a Met (often found in P`1 position of HLE inhibitors), and the increased affinity of this double variant for HLE confirmed our previous observation. Up to now, the most appropriate P3-P`3 sequence for elastase inhibition is CTLMGC; however, it should be noticed that the double variant of PMP-D2 is more powerful than the equivalent double variant of PMP-C K31M/A32G; this is indicative of a sequence and/or conformational effect which influences the reactive site binding loop.

It is noteworthy that although PMP-C, PMP-D2, and HI have several Lys residues in their sequences, and PMP-D2 and HI have an additional Arg, none of these peptides inhibits porcine trypsin. This result is surprising, considering that many natural trypsin inhibitors have a Lys as P1 residue and that most synthetic substrates of trypsin have an Arg as P1 residue.

While this work was in progress, Boigegrain et al. (22) have isolated from the hemolymph of L. migratoria two peptides with sequences identical with PMP-C and PMP-D2. They have shown that both PMP-C and PMP-D2 are powerful inhibitors of alpha-chymotrypsin (K(i) of 0.25 nM and 0.12 nM, respectively) and weak to medium inhibitors of HLE (K(i) > 0.1 µM and of 18 nM, respectively). These values are significantly different from ours. We have shown in this work that PMP-D2 interacts only weakly with alpha-chymotrypsin (K(i) of 1.5 µM) and does not inhibit HLE, and, similarly, PMP-C has a K(i) of 0.12 µM instead of a K(i) > 0.1 µM toward HLE. We have no explanation for this discrepancy.

It will be interesting to further characterize which amino acid(s) outside the reactive site and which part(s) of the framework are essential for the protease inhibitory activity. This should help to design more affine and smaller peptidic analogues or peptidomimetics, which are required for a therapeutic use of these peptides.


FOOTNOTES

*
This work was supported in part by EEC Contract BIO2CT930073. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: Laboratoire de Chimie Organique des Substances Naturelles, Université Louis Pasteur, URA 31 CNRS, 5 rue Blaise Pascal, 67084 Strasbourg Cedex, France. Tel.: 33-88-45-67-35; Fax: 33-88-60-76-20.

(^1)
H. Hietter, M. Schultz, and H. Kunz, submitted for publication.

(^2)
We prefer using ``variant'' instead of ``mutant'' (which refers to a mutational change) since they are obtained by solid-phase synthesis.

(^3)
The abbreviations used are: HLE, human leukocyte elastase; RP-HPLC, reverse phase-high performance liquid chromatography; Fmoc, N-(9-fluorenyl)methoxycarbonyl; DMF, dimethylformamide; DIEA, ethyldiisopropylamine; pNA, para-nitroanilide. It should be mentioned that PMP-C, PMP-D2, and HI are given names of the peptides, rather than abbreviations.

(^4)
G. Mer, H. Hietter, and J.-F. Lefèvre, manuscript in preparation.


ACKNOWLEDGEMENTS

We are grateful to Dr. A. Ménez (CEA, Saclay) for critically reading this manuscript, helpful comments, and his interest in this study. We wish to thank M. Schneider from the Laboratory of Dr. J. Hoffmann (URA 1490, CNRS, Strasbourg) for her precious help in collecting the hemolymph from the locusts. We also express our gratitude to O. Sorokine (URA 31, CNRS, Strasbourg) for the automated sequencing of the peptide named HI.


REFERENCES

  1. Laskowski, M., Jr., and Kato, I. (1980) Annu. Rev. Biochem. 49, 593-626 [CrossRef][Medline] [Order article via Infotrieve]
  2. Bode, W., and Huber, R. (1992) Eur. J. Biochem. 204, 433-451 [Abstract]
  3. Nakakura, N., Hietter, H., Van Dorsselaer, A., and Luu, B. (1992) Eur. J. Biochem. 204, 147-153 [Abstract]
  4. Kromer, E., Nakakura, N., and Lagueux, M. (1994) Insect Biochem. Mol. Biol. 24, 329-331 [Medline] [Order article via Infotrieve]
  5. Kellenberger, C., Hietter, H., Trifilieff, E., and Luu, B. (1994) in Innovations and Perspectives in Solid Phase Synthesis, Biological and Biomedical Applications (Epton, R., ed) pp. 567-570, Mayflower Worldwide Ltd., Birmingham, UK
  6. Mer, G., Kellenberger, C., Koehl, P., Stote, R., Sorokine, O., Van Dorsselaer, A., Luu, B., Hietter, H., and Lefèvre, J.-F. (1994) Biochemistry 33, 15397-15407 [Medline] [Order article via Infotrieve]
  7. Schechter, I., and Berger, A. (1967) Biochem. Biophys. Res. Commun. 27, 157-162 [Medline] [Order article via Infotrieve]
  8. Martodam, R. R., Baugh, R. J., Twumasi, D. Y., and Liener, I. E. (1979) Prep. Biochem. 9, 15-31 [Medline] [Order article via Infotrieve]
  9. Powers, J. C., Boone, R., Carroll, D. L., Gupton, B. F., Kam, C. M., Nishino, N., Sakamoto, M., and Tuhy, P. M. (1984) J. Biol. Chem. 259, 4288-4294 [Abstract/Free Full Text]
  10. Chase, T., Jr., and Shaw, E. (1967) Biochem. Biophys. Res. Commun. 29, 508-514
  11. Schonbaum, G. R., Zerner, B., and Bender, M. L. (1961) J. Biol. Chem. 236, 2930-2935 [Medline] [Order article via Infotrieve]
  12. Van Iersel, J., Jzn, J. F., and Duine, J. A. (1985) Anal. Biochem. 151, 196-204 [Medline] [Order article via Infotrieve]
  13. Bieth, J. G. (1995) Methods Enzymol. 248, 59-84 [CrossRef][Medline] [Order article via Infotrieve]
  14. Bieth, J. G. (1974) in Bayer Symposium V: Proteinase Inhibitors (Fritz, H., Tschesche, H., Greenne, L. J., and Truscheit, E., eds) pp. 463-469, Springer-Verlag, Berlin
  15. Morisson, J. F., and Walsh, C. T. (1988) Adv. Enzymol. Related Areas Mol. Biol. 61, 201-301 [Medline] [Order article via Infotrieve]
  16. Mc Rae, B., Nakajima, K., Travis, J., and Powers, J. C. (1980) Biochemistry 19, 3973-3978 [Medline] [Order article via Infotrieve]
  17. Eisenberg, S. P., Hale, K. K., Heimdal, P., and Thompson, R. C. (1990) J. Biol. Chem. 265, 7976-7981 [Abstract/Free Full Text]
  18. Peanasky, R. J., Bentz, Y., Homandberg, G. A., Minor, S. T., and Babin, D. R. (1984) Arch. Biochem. Biophys. 232, 135-142 [Medline] [Order article via Infotrieve]
  19. Tschesche, H., Beckmann, J., Mehlich, A., Schnabel, E., Truscheit, E., and Wenzel, H. R. (1987) Biochim. Biophys. Acta 913, 97-101 [Medline] [Order article via Infotrieve]
  20. Mc Wherter, C. A., Walkenhorst, W. F., Campbell, E. J., and Glover, G. I. (1989) Biochemistry 28, 5708-5714 [Medline] [Order article via Infotrieve]
  21. Sinha, S., Knops, J., Esch, F., Meyer, E. D., and Oltersdorf, T. (1991) J. Biol. Chem. 266, 21011-21013 [Abstract/Free Full Text]
  22. Boigegrain, R.-A., Mattras, H., Brehélin, M., Paroutaud, P., and ColettiPreviero, M.-A. (1992) Biochem. Biophys. Res. Commun. 189, 790-793 [Medline] [Order article via Infotrieve]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.